All In Biotech

Drug Trial Radar · NCT02112578

Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin

" National, Phase III, Radomized, Double-Blind, Double -Dummy, Controlled, Parallel to Evaluate Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) Soft Gel Capsules in the Control of Acute Vertigo Symphtoms From Peripheral Origin"

Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 292 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

292

Actual

Start

Nov 1, 2016

Primary completion

Apr 1, 2017

Study completion Dec 1, 2017

Sponsor

Lead sponsor
Apsen Farmaceutica S.A.Industry
Sponsor type
Industry
First posted
Apr 14, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

* Evaluation of the non inferiority of Meclin (meclizine) versus Dramin (Dimenhydrinate) to treat the symptoms of acute vertigo from peripheral origin after up to 4 weeks of treatment; * Evaluation of impact on quality of life in vertigo; * Compare the intensity of daytime sleepiness in the two treatment groups; * Compare the efficacy of drugs in relieving each of the 10 symptoms that make up the VS; * Compare the duration of treatment in both treatment groups; * Compare Adehence; * Compare the level of satisfaction from each group from the investigators and the subjects; * Adverse events;

Conditions

  • Vertigo, Peripheral

Interventions

  • MeclizineDrug

    25 mg, 3 times per day up to 30 days

  • DimenhydrinateDrug

    50 mg, 3 times per day up to 30 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Vertigo Score (VS)Time frame: up to 30 days

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Clinilive

    Maringá, Paraná, Brazil

  • Alergoalpha

    Barueri, São Paulo, Brazil

  • Pesquisare Saude S/S Ltda

    Santo André, São Paulo, Brazil

  • ISPEM

    São José dos Campos, São Paulo, Brazil

  • CCBR SP

    São Paulo, São Paulo, Brazil

  • Irmandade da Santa Casa de Misericórdia de São Paulo

    São Paulo, São Paulo, Brazil

  • Clinica de Alergia MarttiAntila

    Sorocaba, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.